- Raw materials
- Hormonal Agents
- Androgens
- Nandrolone decanoate
Nandrolone decanoate API Manufacturers & Suppliers
0 verified results
Get full market intelligence report
All Nandrolone decanoate data. Full access. Full negotiation power
€399,-
This product is listed at the international narcotic list. The purchase and handling are strictly ruled
by national and international laws. Pharmaoffer will validate buyers and suppliers before an order
can be settled.
Commercial-scale Suppliers
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Nandrolone decanoate | CAS No: 360-70-3 | GMP-certified suppliers
A medication that supports management of anemia linked to renal insufficiency and serves as adjunct therapy for senile and postmenopausal osteoporosis in key markets.
Therapeutic categories
Anabolic AgentsAndrogensBone Density Conservation AgentsEstranesEstrenesFused-Ring Compounds
Generic name
Nandrolone decanoate
Molecule type
small molecule
CAS number
360-70-3
DrugBank ID
DB08804
Approval status
Approved drug, Illicit drug
Primary indications
- Nandrolone decanoate is indicated in the management of anemia of renal insufficiency
- In Canada, it is also indicated as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis
Product Snapshot
- This is an intramuscular injectable small‑molecule steroid API
- Its primary uses are in anemia associated with renal insufficiency and, in Canada, as an adjunct in senile and postmenopausal osteoporosis
- It is approved in the US and Canada for specified indications, with some markets also classifying it as an illicit substance outside regulated channels
Clinical Overview
Nandrolone decanoate (CAS 360-70-3) is a steroid ester used clinically for the management of anemia associated with renal insufficiency. In Canada, it is also employed as adjunct therapy in senile and postmenopausal osteoporosis. The decanoate ester provides a prolonged release profile following intramuscular administration, supporting dosing intervals of approximately three to four weeks in approved contexts.
Pharmacologically, nandrolone decanoate acts as an anabolic androgen with a relatively wide therapeutic window. After administration, the ester is hydrolyzed to active nandrolone, a process that may involve PDE7B. Released nandrolone enters cells via receptor‑mediated mechanisms and binds to the androgen receptor. Receptor binding triggers conformational changes that enable nuclear translocation, dimerization, and subsequent interaction with specific DNA sequences to modulate gene transcription. Androgen signaling can also intersect with non‑genomic pathways, including ERK, Akt, and MAPK, contributing to broader regulatory effects on protein synthesis and erythropoiesis.
Absorption from the intramuscular depot is slow and sustained due to the lipophilic decanoate ester. Distribution and metabolism are driven by steroid‑processing pathways, including conjugation via UGT1A1, UGT1A3, UGT1A4, and UGT2B7. The prolonged release profile underlies its extended clinical activity. Elimination occurs through hepatic metabolism and renal excretion of conjugated metabolites.
Safety considerations include potential fluid retention, effects on lipid parameters, and risk of worsening cardiac, renal, or hepatic impairment. Androgenic effects may occur with supratherapeutic exposure or misuse. Acute overdose is uncommon due to the depot formulation, but chronic high‑dose use is associated with well‑characterized anabolic steroid toxicities. The product is approved for medical use but is also encountered in illicit performance‑enhancing settings.
Nandrolone decanoate is marketed globally in injectable depot formulations. For API procurement, sourcing should prioritize verification of ester identity, impurity control specific to steroidal intermediates, and compliance with regional pharmacopoeial specifications to ensure consistent quality for formulation development.
Pharmacologically, nandrolone decanoate acts as an anabolic androgen with a relatively wide therapeutic window. After administration, the ester is hydrolyzed to active nandrolone, a process that may involve PDE7B. Released nandrolone enters cells via receptor‑mediated mechanisms and binds to the androgen receptor. Receptor binding triggers conformational changes that enable nuclear translocation, dimerization, and subsequent interaction with specific DNA sequences to modulate gene transcription. Androgen signaling can also intersect with non‑genomic pathways, including ERK, Akt, and MAPK, contributing to broader regulatory effects on protein synthesis and erythropoiesis.
Absorption from the intramuscular depot is slow and sustained due to the lipophilic decanoate ester. Distribution and metabolism are driven by steroid‑processing pathways, including conjugation via UGT1A1, UGT1A3, UGT1A4, and UGT2B7. The prolonged release profile underlies its extended clinical activity. Elimination occurs through hepatic metabolism and renal excretion of conjugated metabolites.
Safety considerations include potential fluid retention, effects on lipid parameters, and risk of worsening cardiac, renal, or hepatic impairment. Androgenic effects may occur with supratherapeutic exposure or misuse. Acute overdose is uncommon due to the depot formulation, but chronic high‑dose use is associated with well‑characterized anabolic steroid toxicities. The product is approved for medical use but is also encountered in illicit performance‑enhancing settings.
Nandrolone decanoate is marketed globally in injectable depot formulations. For API procurement, sourcing should prioritize verification of ester identity, impurity control specific to steroidal intermediates, and compliance with regional pharmacopoeial specifications to ensure consistent quality for formulation development.
Identification & chemistry
| Generic name | Nandrolone decanoate |
|---|---|
| Molecule type | Small molecule |
| CAS | 360-70-3 |
| UNII | H45187T098 |
| DrugBank ID | DB08804 |
Pharmacology
| Summary | Nandrolone decanoate is a prodrug that releases nandrolone, an anabolic androgen that engages the androgen receptor to modulate gene transcription and downstream signaling pathways. Its pharmacologic activity promotes erythropoiesis and tissue anabolic effects, supporting its use in anemia of renal insufficiency and, in some regions, osteoporosis. Secondary interactions with pathways such as ERK, Akt, and MAPK contribute to its broader transcriptional and metabolic effects. |
|---|---|
| Mechanism of action | Nandrolone decanoate is hydrolyzed to [nandrolone], possibly by PDE7B.Nandrolone is brought into cells by receptor mediated endocytosis, where it interacts with the androgen receptor.After binding to the androgen receptor, a conformational change occurs, the androgen receptor enters the nucleus, dimerizes, and can then bind to segments of DNA to regulate transcription.Androgens can also regulate transcription through activation of ERK, Akt, and MAPK; or binding to and competitively inhibiting transcription factors. |
| Pharmacodynamics | Nandrolone decanoate is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis.It has a long duration of action as it is given every 3-4 weeks, and a wide therapeutic window as acute overdoses are rare.Patients should be counselled regarding the risks of giving this drug to patients with cardiac, renal, or hepatic diseases. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Androgen receptor | Humans | agonist |
| Proto-oncogene c-Fos | Humans | inducer |
| 5-hydroxytryptamine 2 receptor | Humans | modulator |
ADME / PK
| Absorption | A 50 mg intramuscular dose of nandrolone decanoate reaches a mean C<sub>max</sub> 2.14 ng/mL, with a mean T<sub>max</sub> of 30 hours, and a mean AUC of 400 h\*ng/mL.A 100 mg intramuscular dose of nandrolone decanoate reaches a mean C<sub>max</sub> 4.26 ng/mL, with a mean T<sub>max</sub> of 30 hours, and a mean AUC of 862 h\*ng/mL.A 150 mg intramuscular dose of nandrolone decanoate reaches a mean C<sub>max</sub> 5.16 ng/mL, with a mean T<sub>max</sub> of 72 hours, and a mean AUC of 1261 h\*ng/mL. |
|---|---|
| Half-life | Nandrolone decanoate has an absorption half life of 6 days and an elimination half life of 4.3 hours.Alternate studies have shown that nandrolone decanoate has a terminal half life of 7.1, 11.7, and 11.8 hours for doses of 50, 100, and 150 mg respectively. |
| Protein binding | Data regarding the percent protein binding of nandrolone decanoate is not readily available. After nandrolone decanoate is hydrolyzed to [nandrolone], it is bound to sex hormone binding globulin. |
| Metabolism | Nandrolone decanoate is hydrolyzed to [nandrolone], possibly by PDE7B.Nandrolone is further metabolized to the urinary metabolites 19-norandrosterone, 19-noretiocholanolone, and 19-norepiandrosterone.19-norandrosterone is 3-O-glucuronidated by UGT2B7, UGT 1A4, UGT2B4, UGT1A3, and UGT1A1.19-noretiocholanolone is 3-O-glucuronidated by UGT2B7, UGT2B4, UGT1A4, UGT1A10, UGT1A3, and UGT1A1. |
| Route of elimination | Nandrolone decanoate is eliminated as urinary metabolites, however data regarding elimination in the feces are not readily available.Data in cattle shows that [nandrolone] is 30% eliminated in the feces. |
| Clearance | 50 mg, 100 mg, and 150 mg doses of nadrolone decanoate had mean apparent clearances of 80.0 L/h, 74.3 L/h, and 76.2 L/h respectively. |
Formulation & handling
- Nandrolone decanoate is a highly lipophilic steroid ester requiring formulation as an oil-based intramuscular or parenteral solution due to extremely low aqueous solubility.
- The esterified structure provides pro‑drug characteristics with slow in vivo release, supporting depot-type formulations and necessitating attention to solvent and viscosity selection.
- The solid API should be protected from hydrolysis and oxidation during handling, with controlled-temperature storage to maintain ester stability.
Regulatory status
| Lifecycle | Patent protection in the United States and Canada appears to be nearing or past typical expiry timelines, suggesting the API is in a mature phase of its lifecycle. Market activity in both regions is consistent with increasing generic presence and stable, established demand. |
|---|
| Markets | Canada, US |
|---|
Supply Chain
| Supply chain summary | Nandrolone decanoate was originally introduced by a single originator company, but its patents have long expired, and manufacturing is now dominated by multiple generic producers. Branded and non‑branded products are established in markets such as the US and Canada, with historical global availability in many other regions. The long‑expired patent status supports broad existing generic competition across the supply chain. |
|---|
Safety
| Toxicity | Data regarding acute overdose of nandrolone decanoate are not readily available.However, patients experiencing a chronic overdose of anabolic steroids may experience adverse effects including suppression of testosterone and spermatogenesis, shrinking of testicles, decreased libido, and erectile dysfunction in men; and suppressed estrogen, progesterone, and ovulation, amenorrhea, and clitoromegaly in women.Patients may also experience neuropsychiatric, cardiovascular, and hepatic adverse effects.Alkylated anabolic steroids such as nandrolone decanoate are more likely to cause hepatic adverse effects.Treat patients with symptomatic and supportive measures. The intraperitoneal LD<sub>50</sub> in mice is >566 mg/kg. |
|---|
High Level Warnings:
- Chronic high exposure is associated with endocrine suppression, including reduced testosterone production, impaired spermatogenesis, and potential ovarian suppression with virilizing effects
- Neuropsychiatric, cardiovascular, and hepatic toxicities have been observed, with alkylated anabolic steroids showing increased risk for hepatic impairment
- Intraperitoneal LD50 in mice is reported as greater than 566 mg/kg, indicating relatively low acute toxicity in this model but not excluding risk with sustained or excessive exposure
Nandrolone decanoate is a type of Androgens
Androgens are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in hormone replacement therapy and various other medical applications. They are a class of hormones that primarily include testosterone and its derivatives, which are responsible for the development and maintenance of male characteristics in the body.
Androgens are commonly used in the treatment of conditions such as hypogonadism, delayed puberty, androgen deficiency syndromes, and certain types of breast cancer. They work by binding to and activating the androgen receptors in cells, regulating gene expression and influencing the development and functioning of various tissues and organs.
Pharmaceutical companies produce androgens as API compounds to ensure precise dosage and efficacy in pharmaceutical formulations. These APIs undergo rigorous testing and quality control measures to meet regulatory standards and ensure patient safety.
The availability of androgens as APIs enables the formulation of different dosage forms such as tablets, injections, gels, and transdermal patches. These formulations provide healthcare professionals with various options for administration, allowing them to tailor treatment regimens according to individual patient needs.
It is essential for pharmaceutical companies to maintain strict quality control and adhere to Good Manufacturing Practices (GMP) during the production of androgens APIs. This ensures consistent potency, purity, and bioavailability of the APIs, ultimately leading to safe and effective medications for patients.
In conclusion, androgens are a vital subcategory of pharmaceutical APIs used in hormone replacement therapy and the treatment of various medical conditions. Their precise production and formulation allow for effective therapeutic interventions, promoting optimal patient outcomes.
Nandrolone decanoate (Androgens), classified under Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
Frequently asked questions about Nandrolone decanoate API
Sourcing
What matters most when sourcing GMP-grade Nandrolone decanoate?
Key considerations include confirming that the manufacturer operates under GMP appropriate for the US and Canadian regulatory frameworks and can provide complete quality and compliance documentation. Consistent impurity control, validated processes, and reliable batch‑to‑batch reproducibility are essential. Given the broad generic competition, verifying supply chain transparency and the producer’s track record for stable availability is also important.
Which documents are typically required when sourcing Nandrolone decanoate API?
Request the core API documentation set: CoA (4 companies), GMP (3 companies), WC (1 company), MSDS (1 company), BSE/TSE (1 company). Confirm versions and validity dates match the destination market to avoid delays in qualification.
Which manufacturers are known to produce Nandrolone decanoate API?
Known or reported manufacturers for Nandrolone decanoate: Gonane Pharma. Evaluate their GMP history, scale, and regional coverage before requesting dossiers or allocating demand.
How can I request quotes for Nandrolone decanoate API from GMP suppliers?
Submit quote requests through the supplier listings with your specs and required documents (specifications, target volume, delivery timeline, and destination). Providing consistent details upfront speeds comparable offers and clarifies technical feasibility.
Is a GMP audit report available for Nandrolone decanoate manufacturers?
Audit reports may be requested for Nandrolone decanoate: 1 GMP audit report available. Confirm the scope and recency of any audit before relying on it for qualification decisions.
How many suppliers offer Nandrolone decanoate API on Pharmaoffer?
Reported supplier count for Nandrolone decanoate: 4 verified suppliers. Filter listings by certifications, regions, and delivery options to match your qualification plan.
Which countries are known to manufacture Nandrolone decanoate API?
Production countries reported for Nandrolone decanoate: India (2 producers), Hungary (1 producer). Knowing the manufacturing geography helps anticipate logistics lead times and import compliance needs.
Which certifications do suppliers of Nandrolone decanoate usually hold?
Common certifications for Nandrolone decanoate suppliers: CoA (4 companies), GMP (3 companies), WC (1 company), MSDS (1 company), BSE/TSE (1 company). Always verify issuing authorities and expiry dates when reviewing audit packages.
Technical
What is Nandrolone decanoate (CAS 360-70-3) used for?
Nandrolone decanoate is used clinically to treat anemia associated with renal insufficiency. In some regions, such as Canada, it is also used as adjunct therapy for senile and postmenopausal osteoporosis. Its decanoate ester provides prolonged release after intramuscular injection, supporting extended dosing intervals in these approved uses.
Which therapeutic class does Nandrolone decanoate fall into?
Nandrolone decanoate belongs to the following therapeutic categories: Anabolic Agents, Androgens, Bone Density Conservation Agents, Estranes, Estrenes. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.
What conditions is Nandrolone decanoate mainly prescribed for?
The primary indications for Nandrolone decanoate: Nandrolone decanoate is indicated in the management of anemia of renal insufficiency, In Canada, it is also indicated as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.
How does Nandrolone decanoate work?
Nandrolone decanoate is hydrolyzed to [nandrolone], possibly by PDE7B.Nandrolone is brought into cells by receptor mediated endocytosis, where it interacts with the androgen receptor.After binding to the androgen receptor, a conformational change occurs, the androgen receptor enters the nucleus, dimerizes, and can then bind to segments of DNA to regulate transcription.Androgens can also regulate transcription through activation of ERK, Akt, and MAPK; or binding to and competitively inhibiting transcription factors.
What should someone know about the safety or toxicity profile of Nandrolone decanoate?
Nandrolone decanoate has a relatively low acute toxicity in animal models, but sustained or high‑dose exposure can produce clinically significant adverse effects. Chronic use may suppress endogenous sex hormone production, impair spermatogenesis, or cause ovarian suppression with virilization. Neuropsychiatric, cardiovascular, hepatic, and lipid‑related toxicities have been reported, and risks may be greater in individuals with pre‑existing cardiac, renal, or hepatic impairment. Fluid retention and other androgenic effects can occur, particularly with supratherapeutic use or misuse.
What are important formulation and handling considerations for Nandrolone decanoate as an API?
Nandrolone decanoate requires formulation in an oil‑based intramuscular or parenteral solution because of its very low aqueous solubility and lipophilic ester structure. Depot performance depends on appropriate solvent and viscosity selection to support sustained in vivo release. During handling, the solid API should be protected from hydrolysis and oxidation, with controlled‑temperature storage to maintain ester stability.
Is Nandrolone decanoate a small molecule?
Nandrolone decanoate is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.
Are there special stability concerns for oral Nandrolone decanoate?
Yes. Nandrolone decanoate has extremely low aqueous solubility and is intended for oil‑based intramuscular or parenteral formulations, so an oral form would face poor solubility and potential ester hydrolysis. The API also requires protection from hydrolysis and oxidation during handling and controlled‑temperature storage to maintain ester stability.
Regulatory
Where is Nandrolone decanoate approved or in use globally?
Nandrolone decanoate is reported as approved in the following major regions: Canada, US. Understanding geographic coverage informs regulatory filings, supply planning, and risk assessments before escalating procurement.
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Nandrolone decanoate procurement?
Pharmaoffer's Smart Sourcing Service coordinates compliant suppliers, documentation, and competitive quotes for Nandrolone decanoate. It centralizes outreach, follow-ups, and document validation to shorten procurement timelines.
Is Nandrolone decanoate included in the PRO Data Insights coverage?
PRO Data Insights coverage for Nandrolone decanoate: 251 verified transactions across 60 suppliers and 52 buyers worldwide. Use the dataset to benchmark suppliers and monitor regulatory activity where available.
Where can I access the API market report for Nandrolone decanoate?
Market report availability for Nandrolone decanoate: Report Available. The report highlights demand trends, pricing drivers, and supplier landscape insights for procurement planning.
